Cargando…

Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer

BACKGROUND: The enhancement of DNA damage repair is one of the important mechanisms of platinum resistance. Protein cell division cycle 7 (CDC7) is a conserved serine/threonine kinase that plays important roles in the initiation of DNA replication and is associated with chemotherapy resistance in ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junping, Hu, Hong, He, Jinping, Hu, Yuling, Liu, Manting, Cao, Bihui, Chen, Dongni, Ye, Xiaodie, Zhang, Jian, Zhang, Zhiru, Long, Wen, Lian, Hui, Chen, Deji, Chen, Likun, Yang, Lili, Zhang, Zhenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687335/ https://www.ncbi.nlm.nih.gov/pubmed/37992591 http://dx.doi.org/10.1016/j.tranon.2023.101825

Ejemplares similares

Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer
por: Cao, Bihui, et al.
Publicado: (2022)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis
por: Wei, Shuqing, et al.
Publicado: (2017)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
por: Chen, Tao, et al.
Publicado: (2009)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Artesunate-Loaded and Near-Infrared Dye-Conjugated Albumin Nanoparticles as High-Efficiency Tumor-Targeted Photo-Chemo Theranostic Agent
por: Yang, Hainan, et al.
Publicado: (2018)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Cdc6 is sequentially regulated by PP2A-Cdc55, Cdc14, and Sic1 for origin licensing in S. cerevisiae
por: Philip, Jasmin, et al.
Publicado: (2022)

Feasibility and safety of fine positioning needle-mediated breathing control in CT-guided percutaneous puncture of small lung/liver nodules adjacent to diaphragm
por: Wu, Qingde, et al.
Publicado: (2021)

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
por: Deng, Minjie, et al.
Publicado: (2019)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer()
por: Yu, Jun, et al.
Publicado: (2013)

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2023)

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
por: Wong-Brown, Michelle W., et al.
Publicado: (2022)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models
por: Al-Eisawi, Zaynab, et al.
Publicado: (2013)

Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
por: Pandey, Avinash, et al.
Publicado: (2014)

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
por: Fotopoulou, Christina
Publicado: (2014)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Zebrafish cdc6 hypomorphic mutation causes Meier-Gorlin syndrome-like phenotype
por: Yao, Likun, et al.
Publicado: (2017)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
por: Zhang, Jinli, et al.
Publicado: (2017)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
por: Zhang, Jing, et al.
Publicado: (2021)

Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer
por: Xiao, Yangjiong, et al.
Publicado: (2019)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021)

Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
por: Zhang, Xiaoyang, et al.
Publicado: (2017)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
por: Allen, Valerie A., et al.
Publicado: (2016)

Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4
por: Zhou, Songhui, et al.
Publicado: (2020)

Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
por: Schwarzenbach, Heidi, et al.
Publicado: (2019)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q26gbvhi8jdcb21junmir38ehd